Anticancer Effects of Doxorubicin-Loaded Micelle on MCF-7 and MDAMB-231, Breast Cancer Cell Lines
Author(s): Zohreh Amiri, Mehdi Forouzandeh Moghadam, Majid Sadeghizadeh
Breast cancer is one of the most common cancers with high mortality, especially in women. Due to the severe side effects of chemotherapy drugs, scientists have tried to encapsulate these drugs in nanocarriers. The aim of this study was to analyze the anticancer effects of free doxorubicin and the doxorubicin-loaded OA400 micelle on MCF- 7 and MDA-MB-231, breast cancer cell lines. The Drug loading (DL) and Encapsulation efficiency (EE) of DOXloaded micelle were measured by spectrophotometry measurements. Dialysis bag method was used to evaluate the release of doxorubicin. We applied MTT assay in order to evaluate cell cytotoxicity of free and DOX-loaded micelle on MCF-7 and MDA-MB-231, breast cancer cell lines. The hydrophobic doxorubicin were successfully loaded into the OA400 micelles. The DL and EE was obtained 7.32 ±1.36% and 73.2 ±2.6%, respectively. The cumulative release rate of the drug was 27%, 22% and 12% at pHs of 4.5, 5.5 and 7.4, respectively. The IC50 value of the free DOX and DOX-loaded micelle in the MCF-7 cell line was 1.1 μg/ml and 1.8 μg/ml, respectively. Whereas the IC50 value for the free DOX and DOX-loaded micelle on MDA-MB-231 cell line was 1.38 μg/ml and 0.9 μg/ml, respectively. According to the results of this study, DOX-loaded micelle with less side effects had significant antitumor effects on breast cancer cell lines, especially MDA-MB-231 which could be as an alternative option for directed chemotherapy of breast cancer.